The Denmark-based company announced Wednesday it had received a Complete Response Letter for dasiglucagon, which it was proposing for the ultra-rare genetic disease congenital hyperinsulinism, due to the timing of a third-party manufacturing facility reinspection. In an initial visit, the FDA had flagged deficiencies in a third-party contract manufacturer, which the company claims had been resolved by the time of a reinspection in August/September 2024
Q: How many sessions are included
6.2 Tc dng ph Khi ung vi lng khong 3 gram mi ngy, carnitine c th gy ra bun nn, nn ma, chut rt bng, tiu chy, v mi c th c mi nh c
Harris, MRes at AXON Communications, for medical writing and editorial assistance (funded by Novo Nordisk A/S, Denmark)
Boosted with BioPerine for enhanced nutrient uptake, helping your body make the most of each serving